Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-11-10 22:17:55 UTC |
---|
Update Date | 2014-12-24 20:26:12 UTC |
---|
Accession Number | T3D3598 |
---|
Identification |
---|
Common Name | Aflatoxin B1 |
---|
Class | Small Molecule |
---|
Description | Aflatoxins are naturally occurring mycotoxins that are produced by many species of Aspergillus, a fungus, most notably Aspergillus flavus and Aspergillus parasiticus. At least 13 different types of aflatoxin are produced in nature. Aflatoxin B1 is considered the most toxic and is produced by both Aspergillus flavus and Aspergillus parasiticus. The native habitat of Aspergillus is in soil, decaying vegetation, hay, and grains undergoing microbiological deterioration and it invades all types of organic substrates whenever conditions are favorable for its growth. Favorable conditions include high moisture content (at least 7%) and high temperature. Aflatoxins B1 (AFB1) are contaminants of improperly stored foods; they are potent genotoxic and carcinogenic compounds, exerting their effects through damage to DNA. They can also induce mutations that increase oxidative damage. (10). Crops which are frequently affected by Aspergillus contamination include cereals (maize, sorghum, pearl millet, rice, wheat), oilseeds (peanut, soybean, sunflower, cotton), spices (chile peppers, black pepper, coriander, turmeric, ginger), and tree nuts (almond, pistachio, walnut, coconut, brazil nut). |
---|
Compound Type | - Ester
- Ether
- Food Toxin
- Fungal Toxin
- Metabolite
- Mycotoxin
- Natural Compound
- Organic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | AFB1 | AFBI | Aflatoxin b1 |
|
---|
Chemical Formula | C17H12O6 |
---|
Average Molecular Mass | 312.274 g/mol |
---|
Monoisotopic Mass | 312.063 g/mol |
---|
CAS Registry Number | 1162-65-8 |
---|
IUPAC Name | 11-methoxy-6,8,19-trioxapentacyclo[10.7.0.0²,⁹.0³,⁷.0¹³,¹⁷]nonadeca-1,4,9,11,13(17)-pentaene-16,18-dione |
---|
Traditional Name | aflatoxin |
---|
SMILES | COC1=CC2=C(C3C=COC3O2)C2=C1C1=C(C(=O)CC1)C(=O)O2 |
---|
InChI Identifier | InChI=1/C17H12O6/c1-20-10-6-11-14(8-4-5-21-17(8)22-11)15-13(10)7-2-3-9(18)12(7)16(19)23-15/h4-6,8,17H,2-3H2,1H3 |
---|
InChI Key | InChIKey=OQIQSTLJSLGHID-UHFFFAOYNA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as difurocoumarocyclopentenones. These are polycyclic aromatic compounds containing a cyclopenten-2-one ring fused to the coumarin moiety of the difurocoumarin skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Phenylpropanoids and polyketides |
---|
Class | Coumarins and derivatives |
---|
Sub Class | Furanocoumarins |
---|
Direct Parent | Difurocoumarocyclopentenones |
---|
Alternative Parents | |
---|
Substituents | - Difurocoumarocyclopentenone
- Benzopyran
- 1-benzopyran
- Coumaran
- Anisole
- Aryl alkyl ketone
- Aryl ketone
- Alkyl aryl ether
- Pyranone
- Pyran
- Benzenoid
- Heteroaromatic compound
- Dihydrofuran
- Lactone
- Ketone
- Ether
- Acetal
- Oxacycle
- Organoheterocyclic compound
- Organooxygen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organic oxide
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | Crystals. Exhibits blue fluorescence. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | Not Available | Boiling Point | Not Available | Solubility | Not Available | LogP | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-03di-0098000000-ddc3fa0269c995f2f419 | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-03di-0098000000-ddc3fa0269c995f2f419 | 2018-05-18 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-1090000000-8165fc6f4a64219431f5 | 2017-09-01 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-0aor-0039000000-2a3e295d237d548522c8 | 2017-09-14 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-03di-0039000000-e651352b2d5971a2b5fd | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-03dj-0095000000-0bc98f6f0902591a79f9 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-11p1-1190000000-c2826a9129632e518aaa | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-03di-0039000000-d18bfc13c789e0966a83 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-03di-0098000000-0962df76a8d67f37f6cd | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0ufr-2090000000-ba82fd9309bad5df957b | 2016-08-03 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-03fr-7894000000-57075e5f64c138201081 | 2014-09-20 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Oral, dermal, inhalation, and parenteral (contaminated drugs). (8) |
---|
Mechanism of Toxicity | Aflatoxin B1 requires epoxidation to aflatoxin B1 2,3-oxide for activation, which is performed by cytochome P-450 enzymes CYP1A2 and CYP3A4. It produces DNA damage, gene mutation and chromosomal anomalies. Aflatoxins produce singlet oxygen upon their exposure to UV (365-nm) light. Singlet oxygen in turn activates them to mutagens and DNA binding species. Aflatoxin metabolites can intercalate into DNA and alkylate the bases through their epoxide moiety, binding particularity to N7-guanine bases. In addition to randomly mutating DNA, this is thought to cause mutations in the p53 gene, an important gene in preventing cell cycle progression when there are DNA mutations, or signaling apoptosis. Mycotoxins are often able to enter the liver and kidney by human organic anion transporters (hOATs) and human organic cation transporters (hOCTs). They can also inhibit uptake of anions and cations by these transporters, interefering with the secretion of endogenous metabolites, drugs, and xenobiotics including themselves. This results in increased cellular accumulation of toxic compounds causing nephro- and hepatotoxicity. (12, 1, 6, 7) |
---|
Metabolism | After entering the body, aflatoxin B1 is metabolized in the liver by microsomal monooxygenases to the less toxic reactive intermediates aflatoxin M1 and aflatoxin Q1. After aflatoxin B1 is epoxidated to aflatoxin B1 2,3-oxide, it is detoxified by glutathione S-transferases. (12, 15, 6) |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | 1, carcinogenic to humans (16) |
---|
Uses/Sources | The native habitat of Aspergillus is in soil, decaying vegetation, hay, and grains undergoing microbiological deterioration and it invades all types of organic substrates whenever conditions are favorable for its growth. Crops which are frequently affected include cereals (maize, sorghum, pearl millet, rice, wheat), oilseeds (peanut, soybean, sunflower, cotton), spices (chile peppers, black pepper, coriander, turmeric, ginger), and tree nuts (almond, pistachio, walnut, coconut, brazil nut). The toxin can also be found in the milk of animals which are fed contaminated feed. Thus, aflatoxins are usually encountered in thecontext of chronic exposure, via food intake or secondary to the handling of foodstuffs. (15) |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | The main target organ in mammals is the liver so aflatoxicosis is primarily a hepatic disease. Protracted exposure to aflatoxins may cause liver damage and necrosis, cholestasis, and hepatomas. Moreover, protracted exposure to aflatoxins has been associated with hepatocellular carcinoma, acute hepatitis, Reye's syndrome, bile duct cell proliferation, periportal fibrosis, hemorrhages, mucous membrane jaundice, fatty liver changes, cirrhosis in malnourished children, and kwashiorkor. However, aflatoxins accumulate in the presence of liver disease, and the association with hepatic cancer is confounded by the occurrence of hepatitis-B. Thus, it is not clear in these various instances whether aflatoxin is a primary cause of the disease, is an innocent bystander which accumulates secondary to the disease process, or is a contributing cause in conjunction with other factors. It is also mutagenic and teratogenic. Inhaled aflatoxins may produce pulmonary adenomatosis. Aflatoxins modify the immune system by affecting antibody formation, complement, cell-mediated immunity, and phagocytosis. (9, 15) |
---|
Symptoms | A broad range of symptoms can be found depending upon dosage, including, vomiting, abdominal pain, hemorrhage, and pulmonary edema. (14) |
---|
Treatment | Administration of phonobarbital enhances hepatic transformation activities and also protects against AFB-induced toxicity, carcinogenicity and DNA binding in vivo. In cases of ingestion, feeding large quantities of an adsorbent such as activated charcoal may be used. Antioxidants such as ellagic acid and inducers of some cytochromes P450, such as indole-3-carbinol, may give a protective effect. (9, 14) |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
HMDB ID | HMDB06552 |
---|
PubChem Compound ID | 14403 |
---|
ChEMBL ID | Not Available |
---|
ChemSpider ID | 13758 |
---|
KEGG ID | C06800 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 2504 |
---|
BioCyc ID | CPD-4592 |
---|
CTD ID | Not Available |
---|
Stitch ID | Not Available |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Not Available |
---|
References |
---|
Synthesis Reference | Trost, Barry M.; Toste, F. Dean. Palladium Catalyzed Kinetic and Dynamic Kinetic Asymmetric Transformations of g-Acyloxybutenolides. Enantioselective Total Synthesis of (+)-Aflatoxin B1 and B2a. Journal of the American Chemical Society (2003), 125(10), 30 |
---|
MSDS | Link |
---|
General References | - Stark AA, Liberman DF: Synergism between aflatoxins in covalent binding to DNA and in mutagenesis in the photoactivation system. Mutat Res. 1991 Mar;247(1):77-86. [1900569 ]
- Guengerich FP, Johnson WW, Ueng YF, Yamazaki H, Shimada T: Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environ Health Perspect. 1996 May;104 Suppl 3:557-62. [8781383 ]
- Ellis EM, Judah DJ, Neal GE, Hayes JD: An ethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a subfamily of aldo-keto reductases. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10350-4. [8234296 ]
- Hashimoto H, Nakagawa T, Yokoi T, Sawada M, Itoh S, Kamataki T: Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins. Cancer Res. 1995 Feb 15;55(4):787-91. [7850790 ]
- Doyle MP, Marth EH: Degradation of aflatoxin by lactoperoxidase. Z Lebensm Unters Forsch. 1978 Jun 28;166(5):271-3. [685475 ]
- Eaton DL, Gallagher EP: Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol. 1994;34:135-72. [8042848 ]
- Tachampa K, Takeda M, Khamdang S, Noshiro-Kofuji R, Tsuda M, Jariyawat S, Fukutomi T, Sophasan S, Anzai N, Endou H: Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci. 2008 Mar;106(3):435-43. Epub 2008 Mar 5. [18319568 ]
- Peraica M, Domijan AM: Contamination of food with mycotoxins and human health. Arh Hig Rada Toksikol. 2001 Mar;52(1):23-35. [11370295 ]
- Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. [15509185 ]
- Amici M, Cecarini V, Pettinari A, Bonfili L, Angeletti M, Barocci S, Biagetti M, Fioretti E, Eleuteri AM: Binding of aflatoxins to the 20S proteasome: effects on enzyme functionality and implications for oxidative stress and apoptosis. Biol Chem. 2007 Jan;388(1):107-17. [17214555 ]
- Rumack BH POISINDEX(R) Information System Micromedex, Inc., Englewood, CO, 2010; CCIS Volume 143, edition expires Feb, 2010. Hall AH & Rumack BH (Eds): TOMES(R) Information System Micromedex, Inc., Englewood, CO, 2010; CCIS Volume 143, edition expires Feb, 2010.
- International Agency for Research on Cancer (IARC) - Summaries & Evaluations AFLATOXINS [Link]
- DHHS/National Toxicology Program; Eleventh Report on Carcinogens: Aflatoxins (1402-68-2) (January 2005). [Link]
- Aflatoxins: essential data [Link]
- Wikipedia. Aflatoxin. Last Updated 3 May 2010. [Link]
- International Agency for Research on Cancer (2014). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|
Down-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|